Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Ordinary Share Sale Price: £11.91 per share.
- American Depositary Share (ADS) Withholding Price: $33.42 per ADS.
- Transaction Date: February 19, 2009.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine sales of shares by executives to meet tax liabilities following the vesting of Performance Share Plan (PSP) awards.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this filing. The content is strictly a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Type: Sales of Ordinary Shares and withholding of ADSs were executed solely to meet tax liabilities arising from PSP vesting.
- Executive Director Activity: Dr. M. M. Slaoui sold 6,188 Ordinary Shares.
- Other PDMR Activity: Five other individuals sold Ordinary Shares ranging from 1,293 to 2,738 shares each.
- ADS Activity: Mr. W. C. Louv had 990 ADSs withheld.
- Notification Date: The company and relevant parties were advised of these transactions on February 20, 2009.